19.20
前日終値:
$19.14
開ける:
$19.15
24時間の取引高:
350.56K
Relative Volume:
0.59
時価総額:
$1.16B
収益:
$688.00K
当期純損益:
$-170.19M
株価収益率:
-6.4865
EPS:
-2.96
ネットキャッシュフロー:
$-154.68M
1週間 パフォーマンス:
+15.00%
1か月 パフォーマンス:
+22.49%
6か月 パフォーマンス:
+56.87%
1年 パフォーマンス:
-33.21%
Spyre Therapeutics Inc Stock (SYRE) Company Profile
SYRE を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SYRE
Spyre Therapeutics Inc
|
19.18 | 1.16B | 688.00K | -170.19M | -154.68M | -2.96 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.31 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.47 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
331.58 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-09-26 | 開始されました | Deutsche Bank | Buy |
2025-04-08 | 開始されました | Leerink Partners | Outperform |
2025-03-18 | 開始されました | Wolfe Research | Outperform |
2024-09-04 | 開始されました | Wedbush | Outperform |
2024-07-16 | 開始されました | Evercore ISI | Outperform |
2024-05-02 | 開始されました | Robert W. Baird | Outperform |
2024-03-01 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-12-20 | 開始されました | BTIG Research | Buy |
2023-12-11 | 開始されました | Guggenheim | Buy |
2023-12-11 | 開始されました | Jefferies | Buy |
2020-05-04 | 開始されました | Piper Sandler | Overweight |
2019-03-21 | 開始されました | JP Morgan | Overweight |
2018-09-04 | ダウングレード | Wells Fargo | Outperform → Market Perform |
2018-04-24 | 開始されました | Evercore ISI | Outperform |
2018-03-14 | 繰り返されました | Needham | Buy |
すべてを表示
Spyre Therapeutics Inc (SYRE) 最新ニュース
Using Python tools to backtest Spyre Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - newser.com
Will Spyre Therapeutics Inc. stock pay special dividendsNew Guidance & Accurate Buy Signal Notifications - newser.com
Can Spyre Therapeutics Inc. stock sustain free cash flow growth2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Why Spyre Therapeutics Inc. stock is a value investor pickQuarterly Trade Review & High Win Rate Trade Tips - newser.com
What sentiment indicators say about Spyre Therapeutics Inc. stockJuly 2025 Momentum & Short-Term Swing Trade Alerts - newser.com
Best data tools to analyze Spyre Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Will Spyre Therapeutics Inc. stock recover faster than peersMarket Trend Summary & Daily Profit Maximizing Trade Tips - newser.com
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5%Here's Why - MarketBeat
Analyzing Spyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Stock Portfolio Risk Control - newser.com
How to integrate Spyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Is Spyre Therapeutics Inc. a candidate for recovery playWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Custom strategy builders for tracking Spyre Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Spyre Therapeutics' (SYRE) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 8.9%What's Next? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Published on: 2025-10-06 01:19:10 - newser.com
Spyre Therapeutics (SYRE) Highlights Progress at European Gastro - GuruFocus
Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress - Quiver Quantitative
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - The Manila Times
6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior - Stock Titan
Spyre Therapeutics Inc. stock volume spike explainedWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Tools to monitor Spyre Therapeutics Inc. recovery probability2025 Stock Rankings & Smart Money Movement Tracker - newser.com
Spyre Therapeutics Inc. stock daily chart insightsEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilientMarket Risk Analysis & AI Driven Price Predictions - newser.com
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
42,500 Stock Options — Spyre Therapeutics Grants Options at $16.46 to Three Non‑Executive Employees - Stock Titan
What Fibonacci levels say about Spyre Therapeutics Inc. reboundJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
What candlestick patterns are forming on Spyre Therapeutics Inc.Trend Reversal & Weekly High Conviction Ideas - newser.com
Why millennials buy Spyre Therapeutics Inc. (3920) stockTrade Risk Report & Smart Swing Trading Techniques - newser.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $54.29 Average PT from Brokerages - Defense World
What analysts say about Spyre Therapeutics Inc 3920 stockStock Watchlist Updates & Low Risk Capital Growth - earlytimes.in
What technical charts say about Spyre Therapeutics Inc. stockJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Published on: 2025-09-29 23:52:21 - newser.com
Published on: 2025-09-29 23:49:14 - newser.com
Published on: 2025-09-29 13:35:29 - newser.com
Spyre Therapeutics Inc (SYRE) 財務データ
収益
当期純利益
現金流量
EPS
Spyre Therapeutics Inc (SYRE) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Albers Jeffrey W. | Director |
Nov 06 '24 |
Sale |
36.76 |
6,700 |
246,313 |
27,360 |
Albers Jeffrey W. | Director |
Oct 25 '24 |
Sale |
36.43 |
300 |
10,929 |
34,060 |
大文字化:
|
ボリューム (24 時間):